Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia
- Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia
- A total of six participants have been enrolled in the trial across two sites – one in the Netherlands and one in the United Kingdom
Copenhagen, Denmark, 09 May 2025 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech developing an oral therapy for frontotemporal dementia, today announces it has reached an important enrolment milestone in the Ib/IIa phase of its ongoing SORT-IN-2 study of its lead candidate VES001. This Phase Ib/IIa trial is in asymptomatic carriers of a mutation in the progranulin-coding gene (GRN), which causes a leading genetically-determined type of frontotemporal dementia (FTD), called FTD-GRN.
